Scemblix showed a 68% major molecular response rate at 48 weeks, outperforming tyrosine kinase inhibitors by 19%. Common side effects included rash, musculoskeletal pain, and fatigue, with laboratory ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder characterised by the presence of the BCR–ABL fusion gene, which drives aberrant cell proliferation. The advent of targeted therapies ...

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

—In Europe, patients with Philadelphia chromosome-positive CML generally have better rates of survival than similar patients in the U.S. These investigators at MD Anderson Cancer Center tried to ...

A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of ...

The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...

Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp® Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions ...